Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms

Author(s): Rabeet Tariq*

Volume 18, Issue 2, 2023

Published on: 10 May, 2022

Page: [94 - 109] Pages: 16

DOI: 10.2174/2772432817666220321142707

Price: $65

Abstract

Psychedelics might be the oldest psychoactive agents known to be used for inducing religious or mystical experiences. Their strong psychoactive effect was discovered accidentally in 1943 after the synthesis of Lysergic acid diethylamide (LSD) in 1937. These drugs became a mainstream area of research following the synthesis of LSD; however, several political and social factors led to their ban in 1966, after which research on psychedelics remained limited. These drugs became a major topic of scientific and ethical debate in the 1990’s and the recent times have seen a ‘Psychedelic renaissance’ where the therapeutic value of psychedelics is being reconsidered. This article reports the historical perspective of psychedelics, pharmacologic action by 5-HT2A receptor agonism, and psychological effects and compares the proposed therapeutic uses, including uses in depression, PTSD, anxiety- related disorders, drug and alcohol addiction, neurodegenerative diseases, and auto-immune diseases to potential harms including the development of tolerance, hallucinogen persisting perception disorder, and potential psychosis. An analysis of history, pharmacology, and comparison of benefits and harms lead to the conclusion that the potential therapeutic benefits significantly outweigh the potential harms; thus, further research and clinical trials need to be conducted across different countries and cultures for their legal approval in clinical use.

Keywords: Psychedelics, psychotherapy, hallucinogens, pharmacology, psychiatry, psychopharmacology.

« Previous Next »
[1]
Hofmann A. How LSD originated. J Psychedelic Drugs 1979; 11(1-2): 53-60.
[http://dx.doi.org/10.1080/02791072.1979.10472092] [PMID: 392118]
[2]
Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 1957; 66(3): 418-34.
[http://dx.doi.org/10.1111/j.1749-6632.1957.tb40738.x] [PMID: 13425232]
[3]
Carhart-Harris RL. How do psychedelics work? Curr Opin Psychiatry 2019; 32(1): 16-21.
[http://dx.doi.org/10.1097/YCO.0000000000000467] [PMID: 30394903]
[4]
Sessa B. The history of psychedelics in medicine Handbuch Psychoaktive Substanzen Springer Reference Psychologie. Berlin: Springer 2016.
[5]
Sessa B. The psychedelic renaissance: Reassessing the role of psychedelic drugs in 21st century psychiatry and society. Muswell Hill Press, United Kingdom 2012.
[6]
Nichols DE. Psychedelics. Pharmacol Rev 2016; 68(2): 264-355.
[http://dx.doi.org/10.1124/pr.115.011478] [PMID: 26841800]
[7]
Pettigrew J. Iconography in Bradshaw rock art: breaking the circularity. Clin Exp Optom 2011; 94(5): 403-17.
[http://dx.doi.org/10.1111/j.1444-0938.2011.00648.x] [PMID: 21884255]
[8]
Samorini G. Mushroom effigies in world archaeology: from rock art to mushroom-stonesThe stone mushrooms of Thrace EKATAIOS. Alexandroupoli 2012; pp. 16-44.
[9]
Wasson RG, Ingalls DH. The soma of the Rig Veda: what was it? J Am Orient Soc 1971; 91(2): 169-87.
[http://dx.doi.org/10.2307/600096] [PMID: 11623452]
[10]
Hofmann A. Teonanácatl and Ololiuqui, two ancient magic drugs of Mexico. Bull Narc 1971; 23(1): 3-14.
[11]
Schultes RE, Hofmann A. Plants of the gods: origins of hallucinogenic use. New York: McGraw-Hill 1979.
[12]
Stein DL. Psychedelics and the ancient Near East. Astor Blog 2010.
[13]
Spath E. Ueber die Anhalonium-Alkaloide. I. Anhalin and Mezcalin Monatsh Chem 1919; 40: 129-52.
[14]
Beringer K. Der Meskalinrausch, seine Geschichte und Erscheinungsweise. Mescalin intoxication, its history and manifestation. Monogr Gesamtgeb Neurol Psychiatr 1927; 49: 119-315.
[http://dx.doi.org/10.1007/978-3-662-11451-3_6]
[15]
Klüver H. Studies on the eidetic type and on eidetic imagery. Psychol Bull 1928; 25(2): 69.
[http://dx.doi.org/10.1037/h0070849]
[16]
Piper A. Leo Perutz and the Mystery of St Peter’s Snow. Time Mind 2013; 6(2): 175-98.
[http://dx.doi.org/10.2752/175169713X13589680082172]
[17]
Hofmann A. LSD: my problem child (c)1980 by McGraw-Hill Published by McGraw-Hill Book Company ISBN 0-07-029325-2.
[18]
Stall WA. LSD, ein Phantastikum aus der Mutterkorngruppe. Schweizer Archiv fur Nelirologie and Psychiatric 1947; 60: 279.
[19]
Condrau G. Clinical experiences in mental patients with lysergic acid diethylamide. Acta Psychiatr Neurol 1949; 24(9)
[20]
Bush AK, Johnson WC. LSD-25 as an aid in psychotherapy. Dis Nerv Syst 1950; 11: 241-53.
[21]
Twarog BM, Page IH. Serotonin content of some mammalian tissues and urine and a method for its determination. Am J Physiol 1953; 175(1): 157-61.
[http://dx.doi.org/10.1152/ajplegacy.1953.175.1.157] [PMID: 13114371]
[22]
Freedman DX. Effects of LSD-25 on brain serotonin. J Pharmacol Exp Ther 1961; 134(2): 160-6.
[PMID: 13894866]
[23]
Leuner H. Experimental psychosis. Its psychopharmacology, phenomenology, and dynamics in relation to personality. Attempt at a conditional-genetic and functional psychopathology of psychosis. Monogr Gesamtgeb Neurol Psychiatr 1962; 95: 1-275.
[http://dx.doi.org/10.1007/978-3-642-86258-8_1] [PMID: 13929987]
[24]
Sandison RA, Spencer AM, Whitelaw JD. The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1954; 100(419): 491-507.
[http://dx.doi.org/10.1192/bjp.100.419.491] [PMID: 13175011]
[25]
Ling TM, Buckman J. Lysergic Acid (LSD 25) & Ritalin in the Treatment of Neurosis. Lambarde Press 1963.
[26]
Grinspoon L, Bakalar JB. In: Psychedelic drugs reconsidered. New York: Basic Books 1979.
[27]
Shulgin AT, Shulgin A. 2C-I; 2, 5-dimethoxy-4-iodophenethylamine PiHKAL—a chemical love story. Berkeley: Transform Press 1991; pp. 539-42.
[28]
Ingrasci R. Testimony for MDMA hearing submitted by Richard Ingrasci, MD, MPH In the matter of MDMA scheduling 1985.
[29]
Moreno FA, Delgado PL. Hallucinogen-induced relief of obsessions and compulsions. Am J Psychiatry 1997; 154(7): 1037-8.
[http://dx.doi.org/10.1176/ajp.154.7.1037b] [PMID: 9210762]
[30]
Lotsof HS. Ibogaine in the treatment of chemical dependence disorders: Clinical perspectives. MAPS Bulletin 1995; 3: 16-27.
[31]
Grof S. LSD psychotherapy. místo neznámé. (2001): 978-0966001945.
[32]
Sessa B. Can psychedelics have a role in psychiatry once again? Br J Psychiatry 2005; 186(6): 457-8.
[http://dx.doi.org/10.1192/bjp.186.6.457] [PMID: 15928353]
[33]
Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008; 22(6): 621-32.
[http://dx.doi.org/10.1177/0269881108094300] [PMID: 18593735]
[34]
Morris K. Research on psychedelics moves into the mainstream. Lancet 2008; 371(9623): 1491-2.
[http://dx.doi.org/10.1016/S0140-6736(08)60638-8] [PMID: 18459186]
[35]
Tupper KW, Wood E, Yensen R, Johnson MW. Psychedelic medicine: a re-emerging therapeutic paradigm. CMAJ 2015; 187(14): 1054-9.
[http://dx.doi.org/10.1503/cmaj.141124] [PMID: 26350908]
[36]
Gaddum JH. Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. J Physiol 1953; 121(1): 15P.
[PMID: 13085323]
[37]
Gaddum JH, Hameed KA. Drugs which antagonize 5-hydroxytryptamine. Br J Pharmacol Chemother 1954; 9(2): 240-8.
[http://dx.doi.org/10.1111/j.1476-5381.1954.tb00848.x ] [PMID: 13172437]
[38]
Woolley DW, Shaw E. A biochemical and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 1954; 40(4): 228-31.
[http://dx.doi.org/10.1073/pnas.40.4.228] [PMID: 16589461]
[39]
Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984; 35(25): 2505-11.
[http://dx.doi.org/10.1016/0024-3205(84)90436-3] [PMID: 6513725]
[40]
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9(17): 3897-902.
[http://dx.doi.org/10.1097/00001756-199812010-00024] [PMID: 9875725]
[41]
Valle M, Maqueda AE, Rabella M, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol 2016; 26(7): 1161-75.
[http://dx.doi.org/10.1016/j.euroneuro.2016.03.012] [PMID: 27039035]
[42]
Pazos A, Cortés R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985; 346(2): 231-49.
[http://dx.doi.org/10.1016/0006-8993(85)90857-1] [PMID: 4052777]
[43]
Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. J Neurosci 1997; 17(8): 2785-95.
[http://dx.doi.org/10.1523/JNEUROSCI.17-08-02785.1997] [PMID: 9092600]
[44]
Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep 2018; 23(11): 3170-82.
[http://dx.doi.org/10.1016/j.celrep.2018.05.022] [PMID: 29898390]
[45]
Aghajanian GK, Marek GJ. Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 1999; 825(1-2): 161-71.
[http://dx.doi.org/10.1016/S0006-8993(99)01224-X] [PMID: 10216183]
[46]
Celada P, Puig MV, Díaz-Mataix L, Artigas F. The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry 2008; 64(5): 392-400.
[http://dx.doi.org/10.1016/j.biopsych.2008.03.013] [PMID: 18436196]
[47]
Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, et al. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 2013; 33(38): 15171-83.
[http://dx.doi.org/10.1523/JNEUROSCI.2063-13.2013] [PMID: 24048847]
[48]
Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA 2016; 113(17): 4853-8.
[http://dx.doi.org/10.1073/pnas.1518377113] [PMID: 27071089]
[49]
Tagliazucchi E, Roseman L, Kaelen M, et al. Increased global functional connectivity correlates with LSD-induced ego dissolution. Curr Biol 2016; 26(8): 1043-50.
[http://dx.doi.org/10.1016/j.cub.2016.02.010] [PMID: 27085214]
[50]
Carhart-Harris RL, Erritzoe D, Haijen E, Kaelen M, Watts R. Psychedelics and connectedness. Psychopharmacology (Berl) 2018; 235(2): 547-50.
[http://dx.doi.org/10.1007/s00213-017-4701-y] [PMID: 28795211]
[51]
Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014; 8: 20.
[http://dx.doi.org/10.3389/fnhum.2014.00020] [PMID: 24550805]
[52]
Watts A. Psychedelics and religious experience. Calif Law Rev 1968; 56(1): 74.
[http://dx.doi.org/10.2307/3479497]
[53]
Bouso JC, Dos Santos RG, Alcázar-Córcoles MÁ, Hallak JEC. Serotonergic psychedelics and personality: A systematic review of contemporary research. Neurosci Biobehav Rev 2018; 87: 118-32.
[http://dx.doi.org/10.1016/j.neubiorev.2018.02.004] [PMID: 29452127]
[54]
Hollister LE. Effects of hallucinogens in humans. New York: Raven Press 1984; pp. 19-33.
[55]
Grob CS, McKenna DJ, Callaway JC, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 1996; 184(2): 86-94.
[56]
MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011; 25(11): 1453-61.
[http://dx.doi.org/10.1177/0269881111420188] [PMID: 21956378]
[57]
Erritzoe D, Roseman L, Nour MM, et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand 2018; 138(5): 368-78.
[http://dx.doi.org/10.1111/acps.12904] [PMID: 29923178]
[58]
Brengelmann JC. Effects of LSD-25 on tests of personality. J Ment Sci 1958; 104(437): 1226-36.
[http://dx.doi.org/10.1192/bjp.104.437.1226] [PMID: 13621172]
[59]
Bouso JC, Palhano-Fontes F, Rodríguez-Fornells A, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol 2015; 25(4): 483-92.
[http://dx.doi.org/10.1016/j.euroneuro.2015.01.008] [PMID: 25637267]
[60]
Kaiser C, Gold R. Perception, psychedelics and social change. J Psychedelic Drugs 1974; 6(1): 77-81.
[http://dx.doi.org/10.1080/02791072.1974.10471508]
[61]
Hartogsohn I. The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front Neurosci 2018; 12: 129.
[http://dx.doi.org/10.3389/fnins.2018.00129] [PMID: 29559884]
[62]
Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006; 187(3): 268-83.
[http://dx.doi.org/10.1007/s00213-006-0457-5] [PMID: 16826400]
[63]
Huxley A. The doors of perception. Mental (Barbacena) 1952; 98: 2-4.
[64]
Goodman A, Gilman A. Drug addiction and drug abuse. The pharmacological basis of therapeutics 1990.
[65]
Freedman DX. On the use and abuse of LSD. Arch Gen Psychiatry 1968; 18(3): 330-47.
[http://dx.doi.org/10.1001/archpsyc.1968.01740030074008] [PMID: 4295595]
[66]
Garrison KA, Zeffiro TA, Scheinost D, Constable RT, Brewer JA. Meditation leads to reduced default mode network activity beyond an active task. Cogn Affect Behav Neurosci 2015; 15(3): 712-20.
[http://dx.doi.org/10.3758/s13415-015-0358-3] [PMID: 25904238]
[67]
Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, meditation, and self-consciousness. Front Psychol 2018; 9: 1475.
[http://dx.doi.org/10.3389/fpsyg.2018.01475] [PMID: 30245648]
[68]
House RV, Thomas PT, Bhargava HN. Selective modulation of immune function resulting from in vitro exposure to methylenedioxymethamphetamine (Ecstasy). Toxicology 1995; 96(1): 59-69.
[http://dx.doi.org/10.1016/0300-483X(94)02955-T] [PMID: 7863512]
[69]
Yu B, Becnel J, Zerfaoui M, Rohatgi R, Boulares AH, Nichols CD. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-α-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 2008; 327(2): 316-23.
[http://dx.doi.org/10.1124/jpet.108.143461] [PMID: 18708586]
[70]
Nau F Jr, Miller J, Saravia J, et al. Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model. Am J Physiol Lung Cell Mol Physiol 2015; 308(2): L191-8.
[http://dx.doi.org/10.1152/ajplung.00138.2013] [PMID: 25416380]
[71]
Tourino MC, de Oliveira EM, Bellé LP, et al. Tryptamine and dimethyltryptamine inhibit indoleamine 2,3 dioxygenase and increase the tumor-reactive effect of peripheral blood mononuclear cells. Cell Biochem Funct 2013; 31(5): 361-4.
[http://dx.doi.org/10.1002/cbf.2980] [PMID: 23754498]
[72]
Szabo A, Kovacs A, Frecska E, Rajnavolgyi E, Psychedelic N, Psychedelic N. N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One 2014; 9(8): e106533.
[http://dx.doi.org/10.1371/journal.pone.0106533] [PMID: 25171370]
[73]
Wu C, Dias P, Kumar S, Lauder JM, Singh S. Differential expression of serotonin 5-HT2 receptors during rat embryogenesis. Dev Neurosci 1999; 21(1): 22-8.
[http://dx.doi.org/10.1159/000017362] [PMID: 10077698]
[74]
Oufkir T, Arseneault M, Sanderson JT, Vaillancourt C. The 5-HT 2A serotonin receptor enhances cell via bility, affects cell cycle progression and activates MEK-ERK1/2 and JAK2-STAT3 signalling pathways in human choriocarcinoma cell lines. Placenta 2010; 31(5): 439-47.
[http://dx.doi.org/10.1016/j.placenta.2010.02.019] [PMID: 20338635]
[75]
Sonier B, Lavigne C, Arseneault M, Ouellette R, Vaillancourt C. Expression of the 5-HT2A serotoninergic receptor in human placenta and choriocarcinoma cells: mitogenic implications of serotonin. Placenta 2005; 26(6): 484-90.
[http://dx.doi.org/10.1016/j.placenta.2004.08.003] [PMID: 15950062]
[76]
Göőz M, Göőz P, Luttrell LM, Raymond JR. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-α-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 2006; 281(30): 21004.
[77]
Liu Y, Fanburg BL. Phospholipase D signaling in serotonin-induced mitogenesis of pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2008; 295(3): L471-8.
[http://dx.doi.org/10.1152/ajplung.00071.2008] [PMID: 18621911]
[78]
Goodman LS. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: McGraw-Hill 1996.
[79]
Krebs TS, Johansen PØ. Psychedelics and mental health: a population study. PLoS One 2013; 8(8): e63972.
[http://dx.doi.org/10.1371/journal.pone.0063972] [PMID: 23976938]
[80]
Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis 1984; 172(10): 577-95.
[http://dx.doi.org/10.1097/00005053-198410000-00001] [PMID: 6384428]
[81]
Cholden LS, Kurland A, Savage C. Clinical reactions and tolerance to LSD in chronic schizophrenia. J Nerv Ment Dis 1955; 122(3): 211-21.
[http://dx.doi.org/10.1097/00005053-195509000-00001] [PMID: 13295823]
[82]
Belleville RE, Fraser HF, Isbell H, Logan CR, Wikler A. Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. AMA Arch Neurol Psychiatry 1956; 76(5): 468-78.
[http://dx.doi.org/10.1001/archneurpsyc.1956.02330290012002] [PMID: 13371962]
[83]
Angrist B, Rotrosen J, Gershon S. Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacology (Berl) 1974; 36(3): 203-7.
[http://dx.doi.org/10.1007/BF00421802] [PMID: 4844244]
[84]
Appel JB, Freedman DX. Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacology (Berl) 1968; 13(3): 267-74.
[http://dx.doi.org/10.1007/BF00401404] [PMID: 5679628]
[85]
Isbell H, Wolbach AB, Wikler A, Miner EJ. Cross tolerance between LSD and psilocybin. Psychopharmacology (Berl) 1961; 2(3): 147-59.
[http://dx.doi.org/10.1007/BF00407974] [PMID: 13717955]
[86]
Balestrieri A, Fontanari D. Acquired and crossed tolerance to mescaline, LSD-25, and BOL-148. AMA Arch Gen Psychiatry 1959; 1(3): 279-82.
[http://dx.doi.org/10.1001/archpsyc.1959.03590030063008] [PMID: 13796178]
[87]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric 2013.
[88]
G Lerner A. Rudinski D, Bor O, Goodman C. Flashbacks and HPPD: A clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014; 51(4): 296-301.
[PMID: 25841228]
[89]
Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 1969; 126(4): 565-9.
[http://dx.doi.org/10.1176/ajp.126.4.565] [PMID: 5806803]
[90]
G Lerner A. Goodman C, Bor O, Lev-Ran S. Synthetic cannabis substances (SPS) use and hallucinogen persisting perception disorder (HPPD): two case reports. Isr J Psychiatry Relat Sci 2014; 51(4): 277-80.
[PMID: 25841224]
[91]
Coppola M, Mondola R. JWH-122 consumption adverse effects: a case of hallucinogen persisting perception disorder five-year follow-up. J Psychoactive Drugs 2017; 49(3): 262-5.
[http://dx.doi.org/10.1080/02791072.2017.1316431] [PMID: 28441106]
[92]
Lerner AG, Gelkopf M, Skladman I, Rudinski D, Nachshon H, Bleich A. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol 2003; 18(2): 101-5.
[http://dx.doi.org/10.1097/00004850-200303000-00007] [PMID: 12598822]
[93]
Lerner AG, Skladman I, Kodesh A, Sigal M, Shufman E. LSD-induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. Isr J Psychiatry Relat Sci 2001; 38(2): 133-6.
[PMID: 11475916]
[94]
Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345(8948): 476-9.
[http://dx.doi.org/10.1016/S0140-6736(95)90581-2] [PMID: 7710545]
[95]
Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997; 58(2): 85.
[http://dx.doi.org/10.4088/JCP.v58n0206a] [PMID: 9062378]
[96]
Lerner AG, Gelkopf M, Oyffe I, et al. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharmacol 2000; 15(1): 35-7.
[http://dx.doi.org/10.1097/00004850-200015010-00005] [PMID: 10836284]
[97]
Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “endless trip” among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017; 8: 240.
[http://dx.doi.org/10.3389/fpsyt.2017.00240] [PMID: 29209235]
[98]
Halpern JH, Pope HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003; 69(2): 109-19.
[http://dx.doi.org/10.1016/S0376-8716(02)00306-X] [PMID: 12609692]
[99]
Keeler MH. Similarity of schizophrenia and the psilocybin syndrome as determined by objective methods. Int J Neuropsychiatry 1965; 1(6): 630-4.
[PMID: 4380179]
[100]
Bowers MB Jr, Freedman DX. “Psychedelic” experiences in acute psychoses. Arch Gen Psychiatry 1966; 15(3): 240-8.
[http://dx.doi.org/10.1001/archpsyc.1966.01730150016003] [PMID: 5911238]
[101]
Bowers MB Jr. Acute psychosis induced by psychotomimetic drug abuse. I. Clinical findings. Arch Gen Psychiatry 1972; 27(4): 437-40.
[http://dx.doi.org/10.1001/archpsyc.1972.01750280007001] [PMID: 5072710]
[102]
Gouzoulis-Mayfrank E, Habermeyer E, Hermle L, Steinmeyer A, Kunert H, Sass H. Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study. Eur Psychiatry 1998; 13(8): 399-406.
[http://dx.doi.org/10.1016/S0924-9338(99)80686-5] [PMID: 19698655]
[103]
Gouzoulis-Mayfrank E, Hermle L, Thelen B, Sass H. History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry 1998; 31(S 2): 63-8.
[104]
Vollenweider FX, Geyer MA. A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56(5): 495-507.
[http://dx.doi.org/10.1016/S0361-9230(01)00646-3] [PMID: 11750795]
[105]
Arora RC, Meltzer HY. Serotonin 2 (5-HT 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 1991; 85(1): 19-29.
[106]
Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol Psychiatry 1997; 42(7): 529-45.
[http://dx.doi.org/10.1016/S0006-3223(97)00321-1] [PMID: 9376449]
[107]
Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993; 8(4): 315-36.
[http://dx.doi.org/10.1038/npp.1993.32] [PMID: 8512620]
[108]
Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 1993; 50(10): 810-8.
[http://dx.doi.org/10.1001/archpsyc.1993.01820220066007] [PMID: 8215804]
[109]
Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 2008; 29(9): 445-53.
[http://dx.doi.org/10.1016/j.tips.2008.06.006] [PMID: 19086254]
[110]
González-Maeso J, Sealfon SC. Psychedelics and schizophrenia. Trends Neurosci 2009; 32(4): 225-32.
[http://dx.doi.org/10.1016/j.tins.2008.12.005] [PMID: 19269047]
[111]
Vardy MM, Kay SR. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch Gen Psychiatry 1983; 40(8): 877-83.
[http://dx.doi.org/10.1001/archpsyc.1983.01790070067008] [PMID: 6870484]
[112]
Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. Psychol Med 1974; 4(3): 255-61.
[http://dx.doi.org/10.1017/S0033291700042938] [PMID: 4427973]
[113]
Meltzer HY. Role of serotonin in depression. Ann N Y Acad Sci 1990; 600(1 The Neurophar): 486-99.
[http://dx.doi.org/10.1111/j.1749-6632.1990.tb16904.x] [PMID: 2252328]
[114]
Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995; 9 (Suppl. 4): 41-5.
[http://dx.doi.org/10.1097/00004850-199501004-00006] [PMID: 7622823]
[115]
Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994; 40(2): 288-95.
[http://dx.doi.org/10.1093/clinchem/40.2.288] [PMID: 7508830]
[116]
Hrdina PD, Demeter E, Vu TB, Sótónyi P, Palkovits M. 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Res 1993; 614(1-2): 37-44.
[http://dx.doi.org/10.1016/0006-8993(93)91015-K] [PMID: 8348328]
[117]
Sheline YI, Mintun MA, Barch DM, Wilkins C, Snyder AZ, Moerlein SM. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using [18F]altanserin positron emission tomography. Neuropsychopharmacology 2004; 29(12): 2235-41.
[http://dx.doi.org/10.1038/sj.npp.1300555] [PMID: 15367923]
[118]
Stanley M, Mann JJ. Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 1(8318): 214-6.
[http://dx.doi.org/10.1016/S0140-6736(83)92590-4] [PMID: 6130248]
[119]
Attar-Lévy D, Martinot JL, Blin J, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999; 45(2): 180-6.
[http://dx.doi.org/10.1016/S0006-3223(98)00007-9] [PMID: 9951565]
[120]
Meyer JH, Kapur S, Houle S, et al. Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. Am J Psychiatry 1999; 156(7): 1029-34.
[PMID: 10401447]
[121]
Biver F, Wikler D, Lotstra F, Damhaut P, Goldman S, Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br J Psychiatry 1997; 171(5): 444-8.
[http://dx.doi.org/10.1192/bjp.171.5.444] [PMID: 9463603]
[122]
Cameron LP, Benson CJ, DeFelice BC, Fiehn O, Olson DE. Chronic, intermittent microdoses of the psychedelic N, N-Dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci 2019; 10(7): 3261-70.
[http://dx.doi.org/10.1021/acschemneuro.8b00692] [PMID: 30829033]
[123]
Cameron LP, Benson CJ, Dunlap LE, Olson DE. Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci 2018; 9(7): 1582-90.
[http://dx.doi.org/10.1021/acschemneuro.8b00134] [PMID: 29664276]
[124]
Hibicke M, Landry AN, Kramer HM, Talman ZK, Nichols CD. Psychedelics, but Not ketamine, produce persistent antidepressant-like effects in a rodent experimental system for the study of depression. ACS Chem Neurosci 2020; 11(6): 864-71.
[http://dx.doi.org/10.1021/acschemneuro.9b00493] [PMID: 32133835]
[125]
Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3(7): 619-27.
[http://dx.doi.org/10.1016/S2215-0366(16)30065-7] [PMID: 27210031]
[126]
Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep 2017; 7(1): 13187.
[http://dx.doi.org/10.1038/s41598-017-13282-7] [PMID: 29030624]
[127]
Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30(12): 1165-80.
[http://dx.doi.org/10.1177/0269881116675512] [PMID: 27909164]
[128]
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Res 2020; 284: 112749.
[http://dx.doi.org/10.1016/j.psychres.2020.112749] [PMID: 31931272]
[129]
Patra S. Return of the psychedelics: Psilocybin for treatment resistant depression. Asian J Psychiatr 2016; 24: 51-2.
[http://dx.doi.org/10.1016/j.ajp.2016.08.010] [PMID: 27931907]
[130]
Barbosa PC, Mizumoto S, Bogenschutz MP, Strassman RJ. Health status of ayahuasca users. Drug Test Anal 2012; 4(7-8): 601-9.
[http://dx.doi.org/10.1002/dta.1383] [PMID: 22761152]
[131]
Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend 2010; 111(3): 257-61.
[http://dx.doi.org/10.1016/j.drugalcdep.2010.03.024] [PMID: 20554400]
[132]
Osório FL, Sanches RF, Macedo LR, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Br J Psychiatry 2015; 37(1): 13-20.
[http://dx.doi.org/10.1590/1516-4446-2014-1496] [PMID: 25806551]
[133]
Sanches RF, de Lima Osório F, Dos Santos RG, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 2016; 36(1): 77-81.
[http://dx.doi.org/10.1097/JCP.0000000000000436] [PMID: 26650973]
[134]
Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 2019; 49(4): 655-63.
[http://dx.doi.org/10.1017/S0033291718001356] [PMID: 29903051]
[135]
Anderson BT. Ayahuasca as antidepressant? Psychedelics and styles of reasoning in psychiatry. Anthropol Consciousness 2012; 23(1): 44-59.
[http://dx.doi.org/10.1111/j.1556-3537.2012.01056.x]
[136]
dos Santos RG. Safety and side effects of ayahuasca in humans--an overview focusing on developmental toxicology. J Psychoactive Drugs 2013; 45(1): 68-78.
[http://dx.doi.org/10.1080/02791072.2013.763564] [PMID: 23662333]
[137]
Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol 2016; 30(12): 1220-9.
[http://dx.doi.org/10.1177/0269881116679368] [PMID: 27856684]
[138]
Kast E. Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide. Psychiatr Q 1967; 41(4): 646-57.
[http://dx.doi.org/10.1007/BF01575629] [PMID: 4169685]
[139]
Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse 2019; 45(2): 161-9.
[http://dx.doi.org/10.1080/00952990.2018.1545024] [PMID: 30822141]
[140]
Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol 2015; 29(3): 270-9.
[http://dx.doi.org/10.1177/0269881114568039] [PMID: 25744618]
[141]
Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord 2019; 258: 11-24.
[http://dx.doi.org/10.1016/j.jad.2019.07.076] [PMID: 31382100]
[142]
Parekh R. What Are Anxiety Disorders? American Psychiatric Association 2017. Available from: https://www.psychiatry.org/patients-families/anxiety-disorders/what-are-anxiety-disorders
[143]
McGlothlin W, Cohen S, McGlothlin MS. Long lasting effects of LSD on normals. Arch Gen Psychiatry 1967; 17(5): 521-32.
[http://dx.doi.org/10.1001/archpsyc.1967.01730290009002] [PMID: 6054248]
[144]
Santos RG, Landeira-Fernandez J, Strassman RJ, Motta V, Cruz AP. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J Ethnopharmacol 2007; 112(3): 507-13.
[http://dx.doi.org/10.1016/j.jep.2007.04.012] [PMID: 17532158]
[145]
Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ 2001; 165(7): 917-28.
[PMID: 11599334]
[146]
Ho YJ, Pawlak CR, Guo L, Schwarting RK. Acute and long-term consequences of single MDMA administration in relation to individual anxiety levels in the rat. Behav Brain Res 2004; 149(2): 135-44.
[http://dx.doi.org/10.1016/S0166-4328(03)00220-1] [PMID: 15129777]
[147]
Johansen PØ, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol 2009; 23(4): 389-91.
[148]
Danforth AL, Struble CM, Yazar-Klosinski B, Grob CS. MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry 2016; 64: 237-49.
[http://dx.doi.org/10.1016/j.pnpbp.2015.03.011] [PMID: 25818246]
[149]
Boot BP, McGregor IS, Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000; 355(9217): 1818-21.
[http://dx.doi.org/10.1016/S0140-6736(00)02276-5] [PMID: 10832852]
[150]
Stein DJ. Obsessive-compulsive disorder. Lancet 2002; 360(9330): 397-405.
[http://dx.doi.org/10.1016/S0140-6736(02)09620-4] [PMID: 12241794]
[151]
Delgado PL, Moreno FA. Hallucinogens, serotonin and obsessive-compulsive disorder. J Psychoactive Drugs 1998; 30(4): 359-66.
[http://dx.doi.org/10.1080/02791072.1998.10399711] [PMID: 9924841]
[152]
Brandrup E, Vanggaard T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr Scand 1977; 55(2): 127-41.
[http://dx.doi.org/10.1111/j.1600-0447.1977.tb00149.x] [PMID: 842386]
[153]
Wilcox JA. Psilocybin and obsessive compulsive disorder. J Psychoactive Drugs 2014; 46(5): 393-5.
[http://dx.doi.org/10.1080/02791072.2014.963754] [PMID: 25364991]
[154]
Leonard HL, Rapoport JL. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am J Psychiatry 1987; 144(9): 1239-40.
[http://dx.doi.org/10.1176/ajp.144.9.1239b] [PMID: 3631327]
[155]
Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67(11): 1735-40.
[http://dx.doi.org/10.4088/JCP.v67n1110] [PMID: 17196053]
[156]
Kaasa S, Malt U, Hagen S, Wist E, Moum T, Kvikstad A. Psychological distress in cancer patients with advanced disease. Radiother Oncol 1993; 27(3): 193-7.
[http://dx.doi.org/10.1016/0167-8140(93)90073-H] [PMID: 7692472]
[157]
Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115(22): 5349-61.
[http://dx.doi.org/10.1002/cncr.24561] [PMID: 19753617]
[158]
Kast E. LSD and the dying patient. Chic Med Sch Q 1966; 26(2): 80-7.
[PMID: 4163076]
[159]
Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs 1985; 17(4): 279-90.
[http://dx.doi.org/10.1080/02791072.1985.10524332] [PMID: 2418186]
[160]
Pahnke WN, Kurland AA, Unger S, Savage C, Wolf S, Goodman LE. Psychedelic therapy (utilizing LSD) with cancer patients. J Psychedelic Drugs 1970; 3(1): 63-75.
[http://dx.doi.org/10.1080/02791072.1970.10471363]
[161]
Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol 2015; 29(1): 57-68.
[http://dx.doi.org/10.1177/0269881114555249] [PMID: 25389218]
[162]
Gasser P, Holstein D, Michel Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014; 202(7): 513-20.
[http://dx.doi.org/10.1097/NMD.0000000000000113] [PMID: 24594678]
[163]
Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30(12): 1181-97.
[http://dx.doi.org/10.1177/0269881116675513] [PMID: 27909165]
[164]
Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68(1): 71-8.
[http://dx.doi.org/10.1001/archgenpsychiatry.2010.116] [PMID: 20819978]
[165]
Grob CS, Bossis AP, Griffiths RR. Use of the classic hallucinogen psilocybin for treatment of existential distress associated with cancer. 1Psychological aspects of cancer 2013; 291-308.
[166]
Moreton SG, Szalla L, Menzies RE, Arena AF. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics. Psychopharmacology (Berl) 2020; 237(1): 21-32.
[http://dx.doi.org/10.1007/s00213-019-05391-0] [PMID: 31784805]
[167]
Dos Santos RG, Bouso JC, Hallak JEC. Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC Psychiatry 2019; 19(1): 321.
[http://dx.doi.org/10.1186/s12888-019-2288-z] [PMID: 31660905]
[168]
Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 2018; 30(4): 317-30.
[http://dx.doi.org/10.1080/09540261.2018.1482261] [PMID: 30102082]
[169]
Javidi H, Yadollahie M. Post-traumatic stress disorder. Int J Occup Environ Med 2012; 3: 2-9.
[170]
Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol 2013; 27(1): 40-52.
[http://dx.doi.org/10.1177/0269881112464827] [PMID: 23118021]
[171]
Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 2018; 5(6): 486-97.
[http://dx.doi.org/10.1016/S2215-0366(18)30135-4] [PMID: 29728331]
[172]
Mithoefer MC, Wagner MT, Mithoefer AT, et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 2013; 27(1): 28-39.
[http://dx.doi.org/10.1177/0269881112456611] [PMID: 23172889]
[173]
Jerome L, Feduccia AA, Wang JB, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl) 2020; 237(8): 2485-97.
[http://dx.doi.org/10.1007/s00213-020-05548-2] [PMID: 32500209]
[174]
Mithoefer MC, Feduccia AA, Jerome L, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl) 2019; 236(9): 2735-45.
[http://dx.doi.org/10.1007/s00213-019-05249-5] [PMID: 31065731]
[175]
Krediet E, Bostoen T, Breeksema J, van Schagen A, Passie T, Vermetten E. Reviewing the potential of psychedelics for the treatment of PTSD. Int J Neuropsychopharmacol 2020; 23(6): 385-400.
[http://dx.doi.org/10.1093/ijnp/pyaa018] [PMID: 32170326]
[176]
Camí J, Farré M. Drug addiction. N Engl J Med 2003; 349(10): 975-86.
[http://dx.doi.org/10.1056/NEJMra023160] [PMID: 12954747]
[177]
Abuzzahab FS Sr, Anderson BJ. A review of LSD treatment in alcoholism. Int Pharmacopsychiatry 1971; 6(4): 223-35.
[http://dx.doi.org/10.1159/000468273] [PMID: 4950565]
[178]
Hollister LE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. Am J Psychiatry 1969; 125(10): 1352-7.
[http://dx.doi.org/10.1176/ajp.125.10.1352] [PMID: 4886242]
[179]
Ludwig A, Levine J, Stark L, Lazar R. A clinical study of LSD treatment in alcoholism. Am J Psychiatry 1969; 126(1): 59-69.
[http://dx.doi.org/10.1176/ajp.126.1.59] [PMID: 5798383]
[180]
Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26(7): 994-1002.
[http://dx.doi.org/10.1177/0269881112439253] [PMID: 22406913]
[181]
Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry 1973; 28(6): 808-14.
[http://dx.doi.org/10.1001/archpsyc.1973.01750360040005] [PMID: 4575166]
[182]
Alper KR. Ibogaine: a review. Alkaloids Chem Biol 2001; 56: 1-38.
[http://dx.doi.org/10.1016/S0099-9598(01)56005-8] [PMID: 11705103]
[183]
Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR. Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Transl Psychiatry 2016; 6(5): e826.
[http://dx.doi.org/10.1038/tp.2016.71] [PMID: 27244235]
[184]
Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. J Subst Abuse Treat 1994; 11(4): 379-85.
[http://dx.doi.org/10.1016/0740-5472(94)90049-3] [PMID: 7966509]
[185]
Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict 1999; 8(3): 234-42.
[http://dx.doi.org/10.1080/105504999305848] [PMID: 10506904]
[186]
Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse 2018; 44(1): 24-36.
[http://dx.doi.org/10.1080/00952990.2017.1320802] [PMID: 28541119]
[187]
Schenberg EE, de Castro CMA, Chaves BR, da Silveira DX. Treating drug dependence with the aid of ibogaine: a retrospective study. J Psychopharmacol 2014; 28(11): 993-1000.
[http://dx.doi.org/10.1177/0269881114552713] [PMID: 25271214]
[188]
Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol 2008; 115(1): 9-24.
[http://dx.doi.org/10.1016/j.jep.2007.08.034] [PMID: 18029124]
[189]
Alper KR, Lotsof HS. The use of ibogaine in the treatment of addictions. New evidences for hallucinogenic substances as treatments 2007; 2: 43-65.
[190]
Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules 2015; 20(2): 2208-28.
[http://dx.doi.org/10.3390/molecules20022208] [PMID: 25642835]
[191]
Donnelly JR. The need for ibogaine in drug and alcohol addiction treatment. J Leg Med 2011; 32(1): 93-114.
[http://dx.doi.org/10.1080/01947648.2011.550832] [PMID: 21391058]
[192]
Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014; 7(3): 157-64.
[http://dx.doi.org/10.2174/1874473708666150107121331] [PMID: 25563443]
[193]
Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017; 43(1): 55-60.
[http://dx.doi.org/10.3109/00952990.2016.1170135] [PMID: 27441452]
[194]
Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015; 29(3): 289-99.
[http://dx.doi.org/10.1177/0269881114565144] [PMID: 25586396]
[195]
de Veen BT, Schellekens AF, Verheij MM, Homberg JR. Psilocybin for treating substance use disorders? Expert Rev Neurother 2017; 17(2): 203-12.
[http://dx.doi.org/10.1080/14737175.2016.1220834] [PMID: 27684102]
[196]
Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev 2013; 6(1): 30-42.
[http://dx.doi.org/10.2174/15733998113099990003] [PMID: 23627784]
[197]
Argento E, Capler R, Thomas G, Lucas P, Tupper KW. Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug Alcohol Rev 2019; 38(7): 781-9.
[http://dx.doi.org/10.1111/dar.12985] [PMID: 31489731]
[198]
Jones SA, O’Kelly A. Psychedelics as a Treatment for Alzheimer’s Disease Dementia. Front Synaptic Neurosci 2020; 12: 34.
[199]
Family N, Maillet EL, Williams LTJ, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology (Berl) 2020; 237(3): 841-53.
[http://dx.doi.org/10.1007/s00213-019-05417-7] [PMID: 31853557]
[200]
Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf) 2015; 213(3): 561-74.
[http://dx.doi.org/10.1111/apha.12430] [PMID: 25439045]
[201]
Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K. mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 2000; 14(3): 219-24.
[http://dx.doi.org/10.1006/brbi.1999.0579] [PMID: 10970681]
[202]
Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 2018; 30(4): 363-75.
[http://dx.doi.org/10.1080/09540261.2018.1481827] [PMID: 30102081]
[203]
Davydova SM, Cheido MA, Gevorgyan MM, Idova GV. Effects of 5-HT2A receptor stimulation and blocking on immune response. Bull Exp Biol Med 2010; 150(2): 219-21.
[http://dx.doi.org/10.1007/s10517-010-1109-7] [PMID: 21240377]
[204]
Voss EW Jr, Winkelhake JL. Mechanism of lysergic acid diethylamide interference with rabbit antibody biosynthesis. Proc Natl Acad Sci USA 1974; 71(4): 1061-4.
[http://dx.doi.org/10.1073/pnas.71.4.1061] [PMID: 4524614]
[205]
House RV, Thomas PT, Bhargava HN. Immunological consequences of in vitro exposure to lysergic acid diethylamide (LSD). Immunopharmacol Immunotoxicol 1994; 16(1): 23-40.
[http://dx.doi.org/10.3109/08923979409029898] [PMID: 8169321]
[206]
Thompson C, Szabo A. Psychedelics as a novel approach to treating autoimmune conditions. Immunol Lett 2020; 228: 45-54.
[http://dx.doi.org/10.1016/j.imlet.2020.10.001] [PMID: 33035575]
[207]
Schenberg EE. Ayahuasca and cancer treatment. SAGE Open Med 2013; 1: 2050312113508389.
[http://dx.doi.org/10.1177/2050312113508389] [PMID: 26770688]
[208]
Kuypers KP, Ng L, Erritzoe D, et al. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. J Psychopharmacol 2019; 33(9): 1039-57.
[http://dx.doi.org/10.1177/0269881119857204] [PMID: 31303095]
[209]
Cameron LP, Nazarian A, Olson DE. Psychedelic microdosing: prevalence and subjective effects. J Psychoactive Drugs 2020; 52(2): 113-22.
[http://dx.doi.org/10.1080/02791072.2020.1718250] [PMID: 31973684]
[210]
Lea T, Amada N, Jungaberle H, Schecke H, Klein M. Microdosing psychedelics: Motivations, subjective effects and harm reduction. Int J Drug Policy 2020; 75: 102600.
[http://dx.doi.org/10.1016/j.drugpo.2019.11.008] [PMID: 31778967]
[211]
Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Motives and side-effects of microdosing with psychedelics among users. Int J Neuropsychopharmacol 2019; 22(7): 426-34.
[http://dx.doi.org/10.1093/ijnp/pyz029] [PMID: 31152167]
[212]
Rosenbaum D, Weissman C, Anderson T, et al. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities. J Psychopharmacol 2020; 34(6): 612-22.
[http://dx.doi.org/10.1177/0269881120908004] [PMID: 32108529]
[213]
Petranker R, Anderson T, Maier LJ, Barratt MJ, Ferris JA, Winstock AR. Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention. J Psychopharmacol 2020; 269881120953994.
[http://dx.doi.org/10.1177/0269881120953994] [PMID: 33591231]
[214]
Anderson T, Petranker R, Rosenbaum D, et al. Microdosing psychedelics: personality, mental health, and creativity differences in microdosers. Psychopharmacology (Berl) 2019; 236(2): 731-40.
[http://dx.doi.org/10.1007/s00213-018-5106-2] [PMID: 30604183]
[215]
Kaertner LS, Steinborn MB, Kettner H, et al. Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep 2021; 11(1): 1941.
[http://dx.doi.org/10.1038/s41598-021-81446-7] [PMID: 33479342]
[216]
Hutten NRPW, Mason NL, Dolder PC, Kuypers KPC. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front Psychiatry 2019; 10: 672.
[http://dx.doi.org/10.3389/fpsyt.2019.00672] [PMID: 31572246]
[217]
Anderson T, Petranker R, Christopher A, et al. Psychedelic microdosing benefits and challenges: an empirical codebook. Harm Reduct J 2019; 16(1): 43.
[http://dx.doi.org/10.1186/s12954-019-0308-4] [PMID: 31288862]
[218]
Polito V, Stevenson RJ. A systematic study of microdosing psychedelics. PLoS One 2019; 14(2): e0211023.
[http://dx.doi.org/10.1371/journal.pone.0211023] [PMID: 30726251]
[219]
Prochazkova L, Lippelt DP, Colzato LS, Kuchar M, Sjoerds Z, Hommel B. Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting. Psychopharmacology (Berl) 2018; 235(12): 3401-13.
[http://dx.doi.org/10.1007/s00213-018-5049-7] [PMID: 30357434]
[220]
Leary T, Litwin GH, Metzner R. Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 1963; 137(6): 561-73.
[http://dx.doi.org/10.1097/00005053-196312000-00007] [PMID: 14087676]
[221]
Hartogsohn I. Constructing drug effects: A history of set and setting. Drug Sci Policy Law 2017; 3: 2050324516683325.
[http://dx.doi.org/10.1177/2050324516683325]
[222]
Haijen ECHM, Kaelen M, Roseman L, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol 2018; 9: 897.
[http://dx.doi.org/10.3389/fphar.2018.00897] [PMID: 30450045]
[223]
Barrett FS, Preller KH, Kaelen M. Psychedelics and music: neuroscience and therapeutic implications. Int Rev Psychiatry 2018; 30(4): 350-62.
[http://dx.doi.org/10.1080/09540261.2018.1484342] [PMID: 30240282]
[224]
Carhart-Harris RL, Roseman L, Haijen E, et al. Psychedelics and the essential importance of context. J Psychopharmacol 2018; 32(7): 725-31.
[http://dx.doi.org/10.1177/0269881118754710] [PMID: 29446697]
[225]
Kvam TM, Stewart LH, Andreassen OA. Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2018; 138(18)
[226]
Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev 2021; 73(1): 202-77.
[http://dx.doi.org/10.1124/pharmrev.120.000056] [PMID: 33328244]
[227]
Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front Immunol 2015; 6: 358.
[http://dx.doi.org/10.3389/fimmu.2015.00358] [PMID: 26236313]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy